Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo - Summary - MDSpire
Advertisement
Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo
To evaluate the effects of short treatment with Fas ligand on peripheral blood cells to reduce immune cell reactivity and prevent graft-versus-host disease (GvHD) while maintaining engraftment potential, specifically focusing on the mechanisms involved.
Key Findings:
FasL treatment significantly reduced immune cell reactivity in both in vitro and in vivo models, with a notable decrease in specific T-cell subsets and APCs.
The treatment selectively induced apoptosis in specific T-cell subsets and APCs without affecting CD34+ cells, maintaining their viability.
Short treatment with FasL did not compromise the engraftment potential of the cells, as evidenced by successful transplantation outcomes.
Interpretation:
The findings suggest that FasL treatment can effectively uncouple GvHD from GvT effects, potentially allowing for improved outcomes in HSCT without compromising immune reconstitution, which could lead to more effective clinical strategies.
Limitations:
The study primarily focuses on pre-clinical models; clinical applicability needs further validation through human trials.
Long-term effects of FasL treatment on immune reactivity and engraftment in humans remain to be established, and potential biases in sample selection should be considered.
Conclusion:
FasL treatment of MPBCs presents a promising strategy to reduce GvHD while preserving the beneficial effects of T-cell immunity in HSCT, highlighting its potential for improving patient outcomes.
Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.
